Media
The following information is intended as a resource for UK journalists only.
General Press Queries
For general press queries, please contact the AbbVie Corporate Communications team at [email protected] or call us on 01628 925200.
-
NICE Final Draft Guidance recommends ELAHERE®▼ (mirvetuximab soravtansine)
NICE Final Draft Guidance recommends ELAHERE®▼ (mirvetuximab soravtansine), marking the first new treatment recommendation in 20 years for eligible adult patients with platinum-resistant ovarian cancer.
-
AbbVie Appoints Kelly Sanderson Schrems as UK Vice President and General Manager
-
NICE Recommends TEPKINLY®▼ (epcoritamab), a Subcutaneous Bispecific Antibody for Adults With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) After Two or More Lines of Systemic Therapy
-
Allergan Aesthetics’ BOTOX[®] (botulinum toxin type A) receives MHRA approval for the temporary improvement in the appearance of moderate to severe platysma prominence (platysma bands )
UK-ABBV-260070 | February 2026
-
Leave the UK site?
You are now leaving the AbbVie UK corporate website and are being re-directed to an AbbVie UK corporate social media channel. This may contain links to external platforms outside of the control of AbbVie and for which AbbVie is not responsible.
-
Leave the UK site?
You are now leaving the AbbVie UK corporate website and are being re-directed to an AbbVie UK corporate social media channel. This may contain links to external platforms outside of the control of AbbVie and for which AbbVie is not responsible.
-
You are about to be redirected to an AbbVie site.
If you are a UK patient or healthcare professional contacting us with a Medical Information request, you can contact us via [email protected] or 01628 561092
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.
Copyright © 2026 AbbVie Inc. North Chicago, Illinois, U.S.A.
UK-ABBV-260001 | February 2026
